Bayer (OTCPK:BAYRY) submits marketing applications in the U.S. and EU for LCS-16, a new low-dose levonorgestrel-releasing intrauterine system that provides contraception for up to five years. It can be removed at any time and offers a quick return to a woman's normal level of fertility after removal.
Clinical data supporting the submissions showed that the device was 98.5% effective in preventing pregnancy. LCS-16 was generally well-tolerated with no unexpected adverse events reported. Low incidences of ectopic pregnancy, pelvic inflammatory disease, expulsion of the device from the uterus and uterine perforation were observed.
Subscribe for full text news in your inbox